Atrial fibrillation patients’ experiences and perspectives of anticoagulation therapy changes

Satisfaction With Oral Anticoagulants Among Patients With Atrial Fibrillation: A Prospective Observational Study

“…17 Non-AF-specific literature has identified complex medication dosing regimen as negatively associated with satisfaction and a qualitative study in patients with AF identified that more patients were satisfied with the reduced complexity of their therapy when switched from VKA to DOAC. 8,16 The SAKURA AF registry sub-study also showed greater satisfaction with DOACs on the ACTS Burden subscale and no difference on the ACTS benefits subscale, as we also observed. 17 .…”

“…14,15 A pool of evidence has shown that simplified dosage regimens are associated with higher patient satisfaction, including in patients with AF on OACs. 8,16 Several studies have measured AF patients' satisfaction with OACs. 7,[10][11][12][13][17][18][19][20][21][22][23][24][25] However, most suffer from one or more of small sample sizes, lack of (or short) longitudinal observation, retrospective designs, use of unvalidated instruments, and exclusion of certain OACs.…”

Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation

“…Although the literature describes that the effect of SDM on anticoagulation rates and adherence in AF patients is still unknown, some authors mention a potential higher therapy satisfaction, improved adherence and in turn, fewer strokes and bleeding events [47,48].…”

Patient Perspectives on Factors Affecting Direct Oral Anticoagulant Use for Stroke Prevention in Atrial Fibrillation

“…25 Specifically, studies with DOACs showed that prescribers in countries where patients were charged for medicines through insurance were less likely to prescribe DOACs, especially for patients with lower income. [12][13][14][15][16][17]44 However, to our knowledge, no such studies in countries with national health services such as UK were reported. Further research is needed to explore the impact of cost on the uptake of medicines deemed to be cost-effective in settings with national health service.…”

“…11 The average uptake was only 16.5% in 2015 with a high level of unexplained variation across different health economies in England, ranging from 4% to 70% of all OA prescribing. 11 Reported barriers for DOAC use included affordability by patients or health systems, [12][13][14][15][16][17] prescriber's lack of experience or knowledge of anticoagulation, DOAC use or both, 12,[14][15][16][18][19][20] and safety concerns. 9,14,21,22 Other factors that are reported to influence OA prescribing decisions include patient clinical characteristics, [12][13][14][15]19,23 peer prescribing practice, 22 national guidelines and scientific literature, 22 perceived benefits over existing warfarin therapy, 14,22 and practice characteristics.…”